
|Videos|August 30, 2021
Dr. Seth weighs in on onabotulinumtoxinA injections in patients with complex medical backgrounds
Author(s)Urology Times staff
“Botox to [the] bladder has, in some ways, changed the paradigm of treatment for [overactive bladder],” says Jai Seth, MD.
Advertisement
In this video, Jai Seth, MD, discusses the background and objectives of the Neurourology and Urodynamics study, “Intravesical onabotulinumtoxinA injections in patients on antiplatelet and anticoagulation therapy.” Seth is a consultant urological surgeon at St. George’s University hospital, London, UK.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
HHS requests testosterone therapy label updates, citing new safety data
2
Unmet needs and emerging solutions in MRI-guided prostate cancer care
3
Retrospective study suggests differences in OAB therapy persistence among older adults
4
Microbial dysbiosis may predict response to CBM588 in mRCC
5











